---
title: "CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262605977.md"
description: "China Resources Pharmaceutical Group Ltd. (HK:3320) reported a revenue increase to RMB 21.99 billion for the nine months ending September 30, 2025, up from RMB 19.74 billion, despite a net profit decline to RMB 2.90 billion from RMB 3.24 billion. The financial results indicate a decrease in cash and cash equivalents, alongside a rise in total assets and liabilities. Analysts rate the stock as a Hold with a price target of HK$5.50. The company operates in the pharmaceutical sector and has a market cap of HK$30.6 billion."
datetime: "2025-10-24T11:08:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262605977.md)
  - [en](https://longbridge.com/en/news/262605977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262605977.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/262605977.md) | [繁體中文](https://longbridge.com/zh-HK/news/262605977.md)


# CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.

CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from RMB 3.24 billion. The financials highlight a net decrease in cash and cash equivalents and a significant rise in total assets and liabilities, indicating potential adjustments during auditing, and advising caution for shareholders and investors.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Sanjiu Medical & Pharmaceutical Company Limited (CR Sanjiu) is a subsidiary of China Resources Pharmaceutical Group Limited, operating in the pharmaceutical industry. The company is listed on the Shenzhen Stock Exchange and primarily focuses on medical and pharmaceutical products.

**Average Trading Volume:** 16,744,630

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$30.6B

### 相关股票

- [CR Sanjiu (000999.CN)](https://longbridge.com/zh-CN/quote/000999.CN.md)

## 相关资讯与研究

- [China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025](https://longbridge.com/zh-CN/news/275124956.md)
- [Pizu Group Details Tajikistan Mining Loan Deal and Planned 45% Stake in Kanzi Diyor](https://longbridge.com/zh-CN/news/278384508.md)
- [Kainova Therapeutics reports positive phase 1 results for DT‑9081 in advanced solid tumours](https://longbridge.com/zh-CN/news/278526333.md)
- [CATL and Rio Tinto target electrification of mining operations](https://longbridge.com/zh-CN/news/278348983.md)
- [Centre plans national assessment of district hospitals for emergency care](https://longbridge.com/zh-CN/news/278573078.md)